Skip to main content
Dear One Nucleus members, We are delighted to invite you to Collaborate and Network with your Local Community using Connexn - a new online platform to make team-building easy and intuitive. Created by Cambridge University members and alumni and free to use, Connexn allows easy connection for scientists, entrepreneurs, and creatives in Cambridge and beyond. Make connections within the area that is right for you and get help with your hands-on project now!
Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university. The University of Leicester has joined forces with Cambridge-based Isogenica to develop new immunotherapies – a process where the patient’s immune system is helped to fight cancer – which will be tested on a ‘virtual patient’. The virtual patient will be created in the laboratory, by taking samples of a patient’s own tumour cells and immune system, and will then be presented with a range of new immunotherapies developed by the…
Congratulations to the ten startup companies who celebrated the completion of the Stevenage Bioscience Catalyst's Catalyser Programme.  During the programme, each company were supported by a team of mentors to refine their commercialisation strategies before pictching to an audience of investors, experts and invited guests. Read more...
26th edition of the awards recognises the fastest growing technology companies in the UK Deloitte’s 26th annual Technology Fast 50 awards is open for nominations until 1ST September. The awards rank and recognise the 50 fastest growing technology companies in the UK, based on the last four years of revenue growth. Supporting Deloitte’s initiative for the UK’s fastest growing companies are the award sponsors Oracle NetSuite, BGF and HSBC Innovation Banking. Since 1998, the Deloitte Technology Fast 50 awards have showcased an increasingly innovative and diverse range of UK-based technology…
Huge congratulations to the Cambridge Crystallographic Data Centre (CCDC), the University of Leeds, Tianjin University, and AbbVie Inc. who recently won an Outstanding Manuscript Award from the American Association of Pharmaceutical Scientists (AAPS) for a published research paper in the scientific journal Pharmaceutical Research investigating AIDS drug Ritonavir – ‘Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties.’  Dr Jürgen Harter, CEO of CCDC said “This…
Domainex share their latest updates in recent newsletter including:  Receiving a King's Award for Enterprise Expansion plans in UK and US The launch of new Cryo-EM and Flow Cytometry services Latest recruits   Read the full newsletter
Our August eNews is here: 'Embracing Change and Unlocking Opportunities in the Evolving Life Science Industry' ✅ This month's overview from Tony Jones, CEO, One Nucleus✅ Be at Your Best with One Nucleus Events✅ ON Helix 2023 - When do Good Neighbours become Good Business Partners?✅ One Nucleus wins Gold Award for Green Impact✅ The Evolving Role of Online Innovation Workshops via One Nucleus Read it here: https://bit.ly/3KMjntR
OMass Therapeutics Expands Leadership Team with Two New Appointments Appointment of two senior executives in newly created roles Peter Phillips M.D., Ph.D. joins as Senior Vice President of Clinical Development and Julia Sampson Ph.D. joins as Vice President of Non-clinical Development   Oxford, United Kingdom – 02 August 2023 – OMass Therapeutics (‘OMass’, or ‘the Company’), a biotechnology company that identifies medicines against highly validated target ecosystems, today announces the expansion of its leadership team with the appointment of two senior executives in newly…
Leading integrated drug discovery partner, Sygnature Discovery (“Sygnature”) has announced its acquisition of one of North America’s largest discovery Contract Research Organisations, Canada-based NuChem Sciences. This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions and advances their vision to become the global market leader. The transaction creates a significant competitive advantage for Sygnature as it expands its global footprint and business operations to leverage discovery expertise in the North American market. Together,…
Check out a round up of news, updates and highlights from ValiRx this month, including their attendance at ON Helix 2023: ValiRx News Roundup - August 2023 "ValiRx and Inaphaea teams attend On Helix On 6 July, ValiRx CEO Dr Suzy Dilly, Corporate Development Manager Mark Treharne, and Inaphaea's Head of Strategic Development, Dr Andrew Carnegie attended On Helix in Cambridge. The conference, which has become a staple in the life sciences events calendar, addresses the key trends in bio innovation, from developments in life science and technology research to their…